Hepatitis B Diagnosis and Management

Initial Screening and Diagnosis

The initial screening panel for hepatitis B should include HBsAg, anti-HBs, and anti-HBc to determine infection and immunization status, as recommended by Clinical and Molecular Hepatology 1, 2, 3
This combination of tests distinguishes between active infection, past resolved infection with immunity, vaccine-induced immunity, and susceptibility requiring vaccination 1, 2, 3
Active infection is indicated by HBsAg positive, anti-HBc positive, and anti-HBs negative, while past resolved infection with immunity is indicated by anti-HBs positive, anti-HBc positive, and HBsAg negative 1, 2, 3
Vaccine-induced immunity is confirmed by anti-HBs positive, anti-HBc negative, and HBsAg negative 2, 3

Immunity from vaccination is confirmed by anti-HBs positive, anti-HBc negative, and HBsAg negative, as stated by Clinical and Molecular Hepatology 2, 3
Immunity from past infection is indicated by anti-HBs positive, anti-HBc positive, and HBsAg negative, according to Clinical and Molecular Hepatology 2, 3
Chronic HBV infection is defined by HBsAg positive for more than 6 months, anti-HBc positive, and anti-HBs negative, as defined by Clinical and Molecular Hepatology 1, 2, 5

For confirmed chronic HBV infection, additional testing should include HBeAg, anti-HBe, quantitative HBV DNA, liver function tests, complete blood count, and creatinine, as recommended by Clinical and Molecular Hepatology 1, 2, 5
HBeAg positive indicates high viral replication, while anti-HBe positive suggests lower replication, according to Clinical and Molecular Hepatology 1, 2, 8
Quantitative HBV DNA measures viral load, with thresholds of ≥20,000 IU/mL for HBeAg-positive and ≥2,000 IU/mL for HBeAg-negative chronic hepatitis B indicating active disease, as stated by Clinical and Molecular Hepatology 1, 2, 5

Post-vaccination testing is not routinely recommended for immunocompetent adults but is recommended for healthcare workers, dialysis patients, immunocompromised patients, sexual partners of HBV-infected persons, and newborns of HBV-infected mothers, according to Clinical and Molecular Hepatology 7
The target anti-HBs level for protective immunity is ≥10 mIU/mL, as recommended by Clinical and Molecular Hepatology 7
Distinguishing vaccine vs. natural immunity is important for healthcare workers and occupational exposure assessment, with anti-HBs positive alone indicating vaccine-induced immunity and anti-HBs positive + anti-HBc positive indicating natural immunity from past infection, as stated by Clinical and Molecular Hepatology 2, 3